Status:
COMPLETED
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Lead Sponsor:
Pfizer
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be m...
Eligibility Criteria
Inclusion
- Subjects must be at least 18 years of age at screening
- Males and females with clinical evidence of Crohn's disease for at least 3 months duration at screening
- Subjects with moderate to severe Crohn's Disease at baseline, as defined by a Crohn's Disease Activity Index (CDAI) score of 220-450 inclusive
Exclusion
- Subjects currently receiving immunosuppressants, interferon, anti-TNFa
- Subjects with evidence of hematopoietic disorders
- Subjects with evidence of active or latent TB
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00615199
Start Date
January 1 2008
End Date
October 1 2009
Last Update
January 25 2013
Active Locations (72)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
2
Pfizer Investigational Site
Mobile, Alabama, United States, 36617
3
Pfizer Investigational Site
Boulder, Colorado, United States, 80304
4
Pfizer Investigational Site
Lakewood, Colorado, United States, 80215